Twist Bioscience reports record FY2021 revenue $132.3M (+47% YoY), guides FY2022 rev $183M-$193M

Twist Bioscience Corp

2022-FY EPS reported -$3.15 revenue$132,333,000

FY2021 revenue $132.3M, up 47% from $90.1M; net loss $152.1M vs $139.9M.
Q4 revenue $38.0M (+17% YoY); net loss $41.2M ($0.84/share) vs $24.3M ($0.54/share).
FY2022 revenue guidance $183M-$193M, representing ~42% growth at midpoint.
Cash and investments $477.9M at Sept 30, 2021.
Announced acquisition of Abveris to add in vivo antibody discovery capabilities.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.